Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Morgan Stanley

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a note issued to investors on Wednesday, MarketBeat Ratings reports.

Several other analysts also recently weighed in on the company. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Wall Street Zen raised Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $9.77 on Wednesday. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $10.03. The firm has a market capitalization of $38.39 billion, a P/E ratio of -108.54, a P/E/G ratio of 5.05 and a beta of 0.69. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73. The company’s fifty day moving average price is $8.18 and its 200 day moving average price is $7.95.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.